Background Circulating endothelial cells and microparticles have prognostic value in cancer, and might be predictors of response to chemotherapy and antiangiogenic treatments. We have investigated the prognostic value of circulating endothelial cells and microparticles in patients treated for advanced non-small cell lung cancer. Methodology/Principal Findings Peripheral blood samples were obtained from 60 patients before first line, platinum-based chemotherapy +/？ bevacizumab, and after the third cycle of treatment. Blood samples from 60 healthy volunteers were also obtained as controls. Circulating endothelial cells were measured by an immunomagnetic technique and immunofluorescence microscopy. Phosphatidylserine-positive microparticles were evaluated by flow cytometry. Microparticle-mediated procoagulant activity was measured by the endogen thrombin generation assay. Results: pre- and posttreatment levels of markers were higher in patients than in controls (p<0.0001). Elevated levels of microparticles were associated with longer survival. Elevated pretreatment levels of circulating endothelial cells were associated with shorter survival. Conclusions/Significance Circulating levels of microparticles and circulating endothelial cells correlate with prognosis, and could be useful as prognostic markers in patients with advanced non-small cell lung cancer.
References
[1]
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893–2917.
[2]
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92–98.
[3]
Rossi A, Maione P, Bareschino MA, Schettino C, Sacco PC, et al. (2010) The emerging role of histology in the choice of first-line treatment of advanced non-small cell lung cancer: implication in the clinical decision-making. Curr Med Chem 17: 1030–1038.
[4]
Ulahannan SV, Brahmer JR (2011) Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. Cancer Invest 29: 325–337.
[5]
Erdbruegger U, Dhaygude A, Haubitz M, Woywodt A (2010) Circulating endothelial cells: markers and mediators of vascular damage. Curr Stem Cell Res Ther 5: 294–302.
[6]
Goon PK, Lip GY, Boos CJ, Stonelake PS, Blann AD (2006) Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer. Neoplasia 8: 79–88.
[7]
Mancuso P, Bertolini F (2010) Circulating endothelial cells as biomarkers in clinical oncology. Microvasc Res 79: 224–228.
[8]
Mancuso P, Burlini A, Pruneri G, Goldhirsch A, Martinelli G, et al. (2001) Resting and activated endothelial cells are increased in the peripheral blood of cancer patients. Blood 97: 3658–3661.
[9]
Rowand JL, Martin G, Doyle GV, Miller MC, Pierce MS, et al. (2007) Endothelial cells in peripheral blood of healthy subjects and patients with metastatic carcinomas. Cytometry A 71: 105–113.
[10]
Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, et al. (2004) Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. Ann Oncol 15: 139–145.
[11]
Calleri A, Bono A, Bagnardi V, Quarna J, Mancuso P, et al. (2009) Potential of angiogenic growth factors and circulating endothelial cells in breast cancer patients receiving metronomic chemotherapy plus bevacizumab. Clin Cancer Res 15: 7652–7657.
[12]
Ronzoni M, Manzoni M, Mariucci S, Loupakis F, Brugnatelli S, et al. (2010) Circulating endothelial cells and endothelial progenitors as predictive markers of clinical response to bevacizumab-based first-line treatment in advanced colorectal cancer patients. Ann Oncol 21: 2382–2389.
[13]
Matsusaka S, Suenaga M, Mishima Y, Takagi K, Terui Y, et al. (2011) Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer. Chemother Pharmacol 68: 763–768.
[14]
Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, et al. (2009) Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. J Thorac Oncol 4: 208–213.
[15]
Morel O, Toti F, Hugel B, Freyssinet JM (2004) Cellular microparticles: a disseminated storage pool of bioactive vascular effectors. Curr Opin Hematol 11: 156–164.
[16]
Cocucci E, Racchetti G, Meldolesi J (2009) Shedding microvesicles: artefacts no more. Trends Cell Biol 19: 43–51.
[17]
Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9: 581–593.
[18]
Zwaal RF, Schroit AJ (1997) Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89: 1121–1132.
[19]
Davila M, Amirkhosravi A, Coll E, Desai H, Robles L, et al. (2008) Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost 6: 1517–1524.
[20]
Hron G, Kollars M, Weber H, Sagaster V, Quehenberger P, et al. (2007) Tissue factor-positive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost 97: 119–123.
[21]
Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, et al. (2009) Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 15: 6830–6840.
[22]
Chou J, Mackman N, Merrill-Skoloff G, Pedersen B, Furie BC, et al. (2004) Hematopoietic cell-derived microparticle tissue factor contributes to fibrin formation during thrombus propagation. Blood 104: 3190–3197.
[23]
Bidot L, Jy W, Bidot C Jr, Jimenez JJ, Fontana V, et al. (2008) Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis. J Thromb Haemost 6: 913–919.
[24]
Kim HK, Song KS, Park YS, Kang YH, Lee YJ, et al. (2003) Elevated levels of circulating platelet microparticles, VEGF, IL-6 and RANTES in patients with gastric cancer: Possible role of a metastasis predictor. Eur J Cancer 39: 184–191.
[25]
Toth B, Liebhardt S, Steinig K, Ditsch N, Rank A, et al. (2008) Platelet-derived microparticles and coagulation activation in breast cancer patients. Thromb Haemost 100: 663–669.
[26]
Tesselaar ME, Romijn FP, Linden IK, Prins FA, Bertina RM, et al. (2007) Microparticle-associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost 5: 520–527.
[27]
Al-Nedawi K, Meehan B, Rak J (2009) Microvesicles:messengers and mediators of tumor progression. Cell Cycle 8: 2014–2018.
[28]
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors (RECIST Guidelines). J Natl Cancer Inst 92: 205–216.
[29]
Lacroix R, Robert S, Poncelet P, Kasthuri RS, Key NS, et al. (2010) on Behalf Of The ISTH SSC Workshop. Standardization of platelet-derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop. J Thromb Haemost 8: 2571–2574.
[30]
Woywodt A, Blann AD, Kirsch T, Erdbruegger U, Banzet N, et al. (2006) Isolation and enumeration of circulating endothelial cells by immunomagnetic isolation: proposal. J Thromb Haemost 4: 671–677.
[31]
Gy？rgy B, Szabó TG, Pásztói M, Pál Z, Misják P, et al. (2011) Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell. Mol. Life Sci 68: 2667–2688.
[32]
Helley D, Banu E, Bouziane A, Banu A, Scotte F, et al. (2009) Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy. Eur Urol 56: 479–484.
[33]
Guervilly C, Lacroix R, Forel JM, Roch A, Camoin-Jau L, et al. (2011) High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndrome. Crit Care 15: R31.
[34]
Yang Ch, Gagnon C, Hou X, Hardy P (2010) Low density lipoprotein receptor mediates anti-VEGF effect of lymphocyte T-derived microparticles in Lewis lung carcinoma cells. Cancer Biol Ther 10: 448–456.
[35]
Macey MG, Enniks N, Bevan S (2011) Flow cytometric analysis of microparticle phenotype and their role in thrombin generation. Cytometry B Clin Cytom 80: 57–63.
[36]
Pereira J, Alfaro G, Goycoolea M, Quiroga T, Ocqueteau M, et al. (2006) Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state. Thromb Haemost 95: 94–99.
[37]
Ay C, Dunkler D, Simanek R, Thaler J, Koder S, et al. (2011) Prediction of venous thromboembolism in patients with cancer by measuring thrombin generation: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 29: 2099–2103.
